Formålet med studien: This is a Phase 1 trial to investigate the safety and efficacy of the investigational drug, DCC-2618, administered orally (PO), in adult patients with advanced malignancies.
Sponsor: Deciphera Pharmaceuticals LLC
Kontaktopplysninger for rettssaken: Divya Sakamuri; 1-713-745-3296; dsakamuri@mdanderson.org or Filip Janku; 713-563-1930; FJanku@mdanderson.org
Ønsket pasientmedvirkning: ECD patients 18 years or older.
Kjente sentre som tar imot ECD-pasienter i studien: MD Anderson, Houston, Texas
ClinicalTrials.gov-identifikator: NCT02571036

